Home » Contact Us
Speak with a Regulatory Expert
Get expert support with EU MDR, IVDR, UKCA, cosmetics, PPE and global regulatory compliance. Tell us about your product or project, and one of our specialists will contact you within 24 hours.
How can we help you?
Select the area most relevant to your product or regulatory needs.
Medical Devices
EU MDR and UKCA support
In Vitro Diagnostics (IVD)
IVDR and FDA 510(k) support
Cosmetics
EU and UK cosmetic compliance
Personal Protective Equipment (PPE)
EU and UK PPE compliance
Quality Assurance
ISO 13485, ISO/IEC 27001 ISO 9001 support
FDA Submissions
US regulatory strategy and submissions
Request a Quote or Book a Consultation
Tell us about your product and regulatory requirements, and one of our specialists will contact you within 24 hours.
Why contact Patient Guard?
2. A specialist contacts you within 24 hours
3. We arrange a consultation if needed
4. You receive clear next steps
Book a free 30-minute consultation with one of our regulatory experts.
Book a Free ConsultationRequest a Quote or Speak with a Regulatory Expert
Tell us about your product and regulatory requirements, and one of our specialists will contact you within 24 hours.
Our Locations
Patient Guard Ltd
Lancaster House Amy Johnson Way, Blackpool, Lancashire, FY4 2RP. United Kingdom
Company Registration Number: 10654752
Patient Guard Europe UG (haftungsbeschränkt)
Hauffstraße 41, 73765, Neuhausen, Deutschland (Germany)
Company Registration Number: HRB 779309
Supporting EU Market Access via our Germany-based Authorized Representative services.
EUDAMED Authorised Representative SRN: DE-AR-000007523
EUDAMED Importer SRN: DE-IM-000025621
Frequently Asked Questions (FAQs)
How quickly can Patient Guard support a BSI ISO 13485 audit?
Our internal Quality Management team recently led Patient Guard through a successful BSI certification. Depending on your current documentation state, we can typically perform a Gap Analysis within 2–3 weeks to prepare you for Notified Body scrutiny.
Do you provide support for both UKRP and EU Authorised Representative services?
Yes. With physical offices in both Blackpool (UK) and Neuhausen (Germany), we provide seamless dual-market access, acting as your legal representative for both the MHRA and EU Notified Bodies.
Can you help with Clinical Evaluation Reports (CER) for the MDR?
Absolutely. Our clinical specialists are BSI-trained in MDR Clinical Evaluation and IVDR Performance Evaluation. We ensure your technical files meet GSPR requirements and ICH GCP standards for clinical data.
Does your team handle specialized Biocompatibility and Cybersecurity requirements?
Yes. We have in-house expertise in ISO 10993 (Toxicology) and a Lead Auditor for ISO 27001 (Information Security). This integrated approach is essential for modern Software as a Medical Device (SaMD) and high-risk hardware.
Can you help with IVDR Performance Evaluation and Technical Documentation?
Yes. Our team is specifically certified by BSI for the In Vitro Diagnostic Regulation (IVDR). We provide comprehensive support for Performance Evaluation Reports (PER), Scientific Validity, and Analytical/Clinical Performance, ensuring your IVD products meet the rigorous 2026-2027 compliance deadlines.
Do you offer toxicology assessments for ISO 10993 Biocompatibility?
Absolutely. Led by our toxicology and biocompatibility specialist, Steve Condie, we provide expert guidance on ISO 10993-1 testing strategies. We help manufacturers avoid over-testing while ensuring chemical characterization and biological safety requirements are fully satisfied for global submissions.
News from Patient Guard

Why Notified Bodies Reject IVDR Performance Evaluation Reports: The Top 3 Mistakes Manufacturers Make
More than half of IVDR submissions face deficiencies during Notified Body review, with Performance Evaluation Reports (PERs) among the most common areas of concern. Learn the three critical mistakes that lead to PER rejections—including weak State of the Art justification, non-systematic literature reviews, and poor traceability between Scientific Validity, Analytical Performance, and Clinical Performance data—and discover how to build a compliant, audit-ready IVDR technical file.

10 Common Technical Documentation Deficiencies Found During EU MDR and IVDR Notified Body Reviews
Preparing technical documentation for EU MDR or IVDR certification is only half the challenge. Successfully passing a Notified Body review depends on demonstrating consistency across your Quality Management System, Clinical Evaluation, Risk Management, Biological Evaluation, Performance Evaluation and Post-Market Surveillance activities. Discover ten of the most common technical documentation deficiencies identified during MDR and IVDR conformity assessments—and learn how to reduce the likelihood of costly review cycles and certification delays.

EU Authorised Representative Services for Medical Device & IVD Manufacturers
Selling medical devices or IVDs in Europe? If your company is based outside the EU, appointing an EU Authorised Representative (EC Rep) is a legal requirement under EU MDR 2017/745 and IVDR 2017/746. Patient Guard provides expert EU Authorised Representative services, EUDAMED support, regulatory guidance, and ongoing compliance management to help manufacturers access and maintain the European market with confidence.

Predetermined Change Control Plans (PCCPs): The Future of Agile Compliance for Medical Device Software
Learn how PCCPs help medical device software manufacturers manage updates, support AI systems, and enable agile compliance under evolving MDR and UKCA frameworks.

The AI Act Omnibus Explained: What the 2026 EU Rules Mean for Medical Device and IVD Manufacturers
Discover how the EU AI Act Omnibus affects AI medical devices and IVD manufacturers. Learn about the No Duplication principle, transparency rules, key 2026 and 2028 deadlines, and how MDR and IVDR compliance are converging with AI regulation.

Post-Deadline Reality Check: I’ve Submitted My IVDR Class C – Now What?
Submitted your IVDR Class C application? Learn what happens next, common causes of delays, review timelines, and why the September 2026 contract deadline is critical for maintaining EU market access.